Excitatory to inhibitory signaling balance is essential to nervous system function. The G protein-coupled receptor FSHR-1 is the Caenorhabditis elegans ortholog of mammalian glycopeptide hormone receptors and modulates signaling at the C. elegans neuromuscular junction, where excitatory cholinergic and inhibitory GABAergic inputs control muscle excitation. Inhibition of
fshr-1 expression was previously shown to cause reduced muscle contraction and accumulation of fluorescently labeled synaptic vesicles in cholinergic motor neurons. Here, we used a combination of aldicarb-induced paralysis and swimming assays to confirm the neuromuscular defects of
fshr-1(
ok778) loss-of-function mutants, which we found are exacerbated in aged animals, as well as in animals exposed to chronic oxidative stress. Expression of
fshr-1 in all neurons, as well as in cholinergic or GABAergic neurons alone, could restore neuromuscular activity to these animals under normal conditions. Surprisingly, however, this same
fshr-1 re-expression in cholinergic or GABAergic neurons failed to restore wild type synaptic vesicle localization, and endogenous
fshr-1 expression was detected in what appear to be pharyngeal neurons and arcade cells but not in body wall motor neurons, suggesting a complex site of action.
fshr-1(
ok778) mutants also exhibited build-up of the synaptic vesicle priming factor, UNC-10/RIM, and its interaction partner, SYD-2/Liprinalpha, primarily in cholinergic motor neurons. No such effects were observed for the active zone protein, CLA-1/Clarinet, or the INS-22 dense core vesicle marker. Finally, gain-of-function mutations in
gsa-1/GaS or
acy-1/adenylyl cyclase suppressed the reduced muscle excitation of
fshr-1 mutants. Together, these data support a model in which FSHR-1 may act cell non-autonomously, as well as in body wall motor neurons, to promote muscle excitation upstream of GSA-1 and ACY-1, ultimately controlling UNC-10 localization and cholinergic vesicle release. We are currently further exploring FSHR-1 site(s) of action, working to identify potential ligands that may control FSHR-1's neuromuscular effects, as well as investigating potential connections of FSHR-1 to lipid signaling and other stress-related pathways as they relate to neuromuscular and other neuronal signaling events in physiological and stress conditions.